Thursday, August 30, 2012
Monday, August 20, 2012
OK, NURSE MARYANNE, YOU OLD BAT, THIS IS RSD, YOU FREAKING MORON
IF I ever see that BITCH again, I swear to God and all thing holy I will knock the SHIT out of her, like I SHOULD HAVE last week.
They are not worth this:
Wednesday, August 15, 2012
Medical Marijuana and Osteoporosis
Medical Marijuana and Osteoporosis
Osteoporosis is a degenerative skeletal disease characterized by a deterioration of bone tissue. Patients with osteoporosis are at risk for suffering multiple fractures and other serious disabilities. Approximately 10 million Americans over age 50 suffer from osteoporosis, according to the US Surgeon General’s office, and another 34 million are at risk for developing the disease.
Initial references regarding the potential use of cannabinoids to protect against the onset of osteoporosis are available in the scientific literature beginning in the early 1990s. To date, however, no clinical work has taken place investigating the use of cannabis for this indication.
Writing in the January 2006 issue of the Proceedings of the National Academy of Sciences, investigators at the Bone Laboratory of the Hebrew University in Jerusalem reported that the administration of the synthetic cannabinoid agonist HU-308 slowed the development of osteoporosis, stimulated bone building, and reduced bone loss in animals. Follow up research published in the Annals of the New York Academy of Sciences in 2007 reported that the activation of the CB2 cannabinoid receptor reduced experimentally-induced bone loss and stimulated bone formation. Investigators have previously reported that mice deficient in the CB2 cannabinoid receptor experienced age-accelerated bone loss reminiscent of human osteoporosis.
Though the role of the endocannabinoid system in the regulation of bone mass is not yet well understood, experts are hopeful that cannabinoids and the cannabinoid receptor system may be "A promising target novel target for anti-osteoporotic drug development."
Osteoporosis is a degenerative skeletal disease characterized by a deterioration of bone tissue. Patients with osteoporosis are at risk for suffering multiple fractures and other serious disabilities. Approximately 10 million Americans over age 50 suffer from osteoporosis, according to the US Surgeon General’s office, and another 34 million are at risk for developing the disease.
Initial references regarding the potential use of cannabinoids to protect against the onset of osteoporosis are available in the scientific literature beginning in the early 1990s. To date, however, no clinical work has taken place investigating the use of cannabis for this indication.
Writing in the January 2006 issue of the Proceedings of the National Academy of Sciences, investigators at the Bone Laboratory of the Hebrew University in Jerusalem reported that the administration of the synthetic cannabinoid agonist HU-308 slowed the development of osteoporosis, stimulated bone building, and reduced bone loss in animals. Follow up research published in the Annals of the New York Academy of Sciences in 2007 reported that the activation of the CB2 cannabinoid receptor reduced experimentally-induced bone loss and stimulated bone formation. Investigators have previously reported that mice deficient in the CB2 cannabinoid receptor experienced age-accelerated bone loss reminiscent of human osteoporosis.
Though the role of the endocannabinoid system in the regulation of bone mass is not yet well understood, experts are hopeful that cannabinoids and the cannabinoid receptor system may be "A promising target novel target for anti-osteoporotic drug development."
Medical Marijuana and Chronic Pain
Medical Marijuana and Chronic Pain
As many as one in five Americans lives with chronic pain. Many of these people suffer from neuropathic pain (nerve-related pain) -- a condition that is associated with numerous diseases, including diabetes, cancer, multiple sclerosis, and HIV. In most cases, the use of standard analgesic medications such as opiates and NSAIDS (non-steroidal anti-inflammatory drugs) is ineffective at relieving neuropathic pain.
Survey data indicates that the use of cannabis is common in chronic pain populations, and several recent clinical trials indicate that inhaled marijuana can significantly alleviate neuropathic pain. A pair of clinical trials recently demonstrated that smoking cannabis reduces neuropathic pain in patients with HIV by more than 30 percent compared to placebo.
In 2008 investigators at the University of California at Davis assessed the efficacy of inhaled cannabis on pain intensity among 38 patients with central or peripheral neuropathic pain in a randomized, placebo-controlled, crossover trial. They reported: "[C]annabis reduced pain intensity and unpleasantness equally. Thus, as with opioids, cannabis does not rely on a relaxing or tranquilizing effect, but rather reduces both the core component of nociception (nerve pain) and the emotional aspect of the pain experience to an equal degree."
Preclinical data indicates that cannabinoids, when administered in concert with one another, are more effective at ameliorating neuropathic pain than the use of a single agent. Investigators at the University of Milan reported in 2008 that the administration of single cannabinoids such as THC or CBD produce limited relief compared to the administration of plant extracts containing multiple cannabinoids, terpenes (oils), and flavonoids (pigments).
Researchers concluded: "[T]he use of a standardized extract of Cannabis sativa ... evoked a total relief of thermal hyperalgesia, in an experimental model of neuropathic pain, ... ameliorating the effect of single cannabinoids," investigators concluded. ... "Collectively, these findings strongly support the idea that the combination of cannabinoid and non-cannabinoid compounds, as present in [plant-derived] extracts, provide significant advantages in the relief of neuropathic pain compared with pure cannabinoids alone."
In 2009, an international team of investigators from the United Kingdom, Belgium, and Romania affirmed these preclinical findings in a clinical study of intractable cancer pain patients. They concluded: "[I]n this study, the THC/CBD extract showed a more promising efficacy profile than the THC extract alone. This finding is supported by evidence of additional synergy between THC and CBD. CBD may enhance the analgesic potential of THC by means of potent inverse agonism at CB2 receptors, which may produce anti-inflammatory effects, along with its ability to inhibit immune cell migration. ... These results are very encouraging and merit further study."
As many as one in five Americans lives with chronic pain. Many of these people suffer from neuropathic pain (nerve-related pain) -- a condition that is associated with numerous diseases, including diabetes, cancer, multiple sclerosis, and HIV. In most cases, the use of standard analgesic medications such as opiates and NSAIDS (non-steroidal anti-inflammatory drugs) is ineffective at relieving neuropathic pain.
Survey data indicates that the use of cannabis is common in chronic pain populations, and several recent clinical trials indicate that inhaled marijuana can significantly alleviate neuropathic pain. A pair of clinical trials recently demonstrated that smoking cannabis reduces neuropathic pain in patients with HIV by more than 30 percent compared to placebo.
In 2008 investigators at the University of California at Davis assessed the efficacy of inhaled cannabis on pain intensity among 38 patients with central or peripheral neuropathic pain in a randomized, placebo-controlled, crossover trial. They reported: "[C]annabis reduced pain intensity and unpleasantness equally. Thus, as with opioids, cannabis does not rely on a relaxing or tranquilizing effect, but rather reduces both the core component of nociception (nerve pain) and the emotional aspect of the pain experience to an equal degree."
Preclinical data indicates that cannabinoids, when administered in concert with one another, are more effective at ameliorating neuropathic pain than the use of a single agent. Investigators at the University of Milan reported in 2008 that the administration of single cannabinoids such as THC or CBD produce limited relief compared to the administration of plant extracts containing multiple cannabinoids, terpenes (oils), and flavonoids (pigments).
Researchers concluded: "[T]he use of a standardized extract of Cannabis sativa ... evoked a total relief of thermal hyperalgesia, in an experimental model of neuropathic pain, ... ameliorating the effect of single cannabinoids," investigators concluded. ... "Collectively, these findings strongly support the idea that the combination of cannabinoid and non-cannabinoid compounds, as present in [plant-derived] extracts, provide significant advantages in the relief of neuropathic pain compared with pure cannabinoids alone."
In 2009, an international team of investigators from the United Kingdom, Belgium, and Romania affirmed these preclinical findings in a clinical study of intractable cancer pain patients. They concluded: "[I]n this study, the THC/CBD extract showed a more promising efficacy profile than the THC extract alone. This finding is supported by evidence of additional synergy between THC and CBD. CBD may enhance the analgesic potential of THC by means of potent inverse agonism at CB2 receptors, which may produce anti-inflammatory effects, along with its ability to inhibit immune cell migration. ... These results are very encouraging and merit further study."
Medical Marijuana and Dystonia
Medical Marijuana and Dystonia
Dystonia is a neurological movement disorder characterized by abnormal muscle tension and involuntary, painful muscle contractions. It is the third most common movement disorder after Parkinson's disease and tremor, affecting more than 300,000 people in North America.
A small number of case reports and preclinical studies investigating the use of cannabis and cannabinoids for symptoms of dystonia are referenced in the recent scientific literature. A 2002 case study published in the July issue of the The Journal of Pain and Symptom Management reported improved symptoms of dystonia after smoking cannabis in a 42-year-old chronic pain patient. Investigators reported that subject’s subjective pain score fell from 9 to zero (on a zero-to-10 visual analog scale) following cannabis inhalation, and that the subject did not require any additional analgesic medication for the following 48 hours. "No other treatment intervention to date had resulted in such dramatic overall improvement in [the patient's] condition," investigators concluded.
A second case study reporting “significant clinical improvement” following cannabis inhalation in a single 25-year-old patient with generalized dystonia due to Wilson’s disease was documented by an Argentinian research team in the August 2004 issue of the journal Movement Disorders.
Also in 2004, a German research team at the Hannover Medical School reported successful treatment of musician’s dystonia in a 38-year-old professional pianist following administration of 5 mg of THC in a placebo-controlled single-dose trial. Investigators reported “clear improvement of motor control” in the subject’s affected hand, and noted, “[Two] hours after THC intake, the patient was able to play technically demanding literature, which had not been possible before treatment.” Prior to cannabinoid treatment, the subject had been unresponsive to standard medications and was no longer performing publicly. “The results provide evidence that … THC intake … significantly improves [symptoms of] … focal dystonia,” investigators concluded.
By contrast, a 2002 randomized, placebo-controlled study investigating the use of the synthetic oral cannabinoid naboline (Cessamet) in 15 patients afflicted with generalized and segmental primary dystonia did not show a significant reduction in dystonic symptoms. Investigators speculated that this result may have been dose-related, and that administration of a higher dosage may have yielded a different outcome.
At least one recent preclinical trial indicates that both synthetic cannabinoids as well as high doses of the natural non-psychoactive cannabinoid cannabidiol (CBD) could moderate the disease progression of dystonia in animals.[5] Limited references regarding the use of cannabinoids for dystonia in humans[6] and animals[7] in the 1980s and the 1990s also appear in the scientific literature. It would appear that additional, larger clinical trials are warranted to investigate the use of cannabis and cannabinoids for this indication.
http://www.kindgreenbuds.com/medical-marijuana/dystonia.html
Dystonia is a neurological movement disorder characterized by abnormal muscle tension and involuntary, painful muscle contractions. It is the third most common movement disorder after Parkinson's disease and tremor, affecting more than 300,000 people in North America.
A small number of case reports and preclinical studies investigating the use of cannabis and cannabinoids for symptoms of dystonia are referenced in the recent scientific literature. A 2002 case study published in the July issue of the The Journal of Pain and Symptom Management reported improved symptoms of dystonia after smoking cannabis in a 42-year-old chronic pain patient. Investigators reported that subject’s subjective pain score fell from 9 to zero (on a zero-to-10 visual analog scale) following cannabis inhalation, and that the subject did not require any additional analgesic medication for the following 48 hours. "No other treatment intervention to date had resulted in such dramatic overall improvement in [the patient's] condition," investigators concluded.
A second case study reporting “significant clinical improvement” following cannabis inhalation in a single 25-year-old patient with generalized dystonia due to Wilson’s disease was documented by an Argentinian research team in the August 2004 issue of the journal Movement Disorders.
Also in 2004, a German research team at the Hannover Medical School reported successful treatment of musician’s dystonia in a 38-year-old professional pianist following administration of 5 mg of THC in a placebo-controlled single-dose trial. Investigators reported “clear improvement of motor control” in the subject’s affected hand, and noted, “[Two] hours after THC intake, the patient was able to play technically demanding literature, which had not been possible before treatment.” Prior to cannabinoid treatment, the subject had been unresponsive to standard medications and was no longer performing publicly. “The results provide evidence that … THC intake … significantly improves [symptoms of] … focal dystonia,” investigators concluded.
By contrast, a 2002 randomized, placebo-controlled study investigating the use of the synthetic oral cannabinoid naboline (Cessamet) in 15 patients afflicted with generalized and segmental primary dystonia did not show a significant reduction in dystonic symptoms. Investigators speculated that this result may have been dose-related, and that administration of a higher dosage may have yielded a different outcome.
At least one recent preclinical trial indicates that both synthetic cannabinoids as well as high doses of the natural non-psychoactive cannabinoid cannabidiol (CBD) could moderate the disease progression of dystonia in animals.[5] Limited references regarding the use of cannabinoids for dystonia in humans[6] and animals[7] in the 1980s and the 1990s also appear in the scientific literature. It would appear that additional, larger clinical trials are warranted to investigate the use of cannabis and cannabinoids for this indication.
http://www.kindgreenbuds.com/medical-marijuana/dystonia.html
Marijuana Strain Library -Brains Es Marijuana Strain
Marijuana Strain Library - Brains Escape Marijuana Strain
Through the 1900s, Switzerland seemed to be on the verge of a progressive marijuana policy, indeed of becoming the next pot spot. KC Brains was among several growers who bred Swiss seeds in anticipation of a more liberal legal climate. Edelweiss is a distinctive Swiss strain that emerged in this period, based on a Swiss indica with a strong local reputation. Unfortunately, the Swiss government retreated from looser cannabis laws and began to crack down on pot culture, especially if it was "imported". Many growers who had tested Switzerland's evolving pot policies were charged as criminals or shown to the border.
KC Brains brought Edelweiss with him back to Holland, where he combined it with KC 606 and a Brazilian strain seasoned with sativa from South Ecuador.
The result is a fresh lemon weed whose buzz feels more "high" than "stoned". The Brains Escape pattern of growth is decidedly indica, delivering big plants with incredibly wide, dark, fat leaves. This strain's long growing season rewards outdoor growers who vegetate starter plants indoors or in a greenhouse, and then transplant outside to flower for 9-12 weeks before the frost starts.
This is an enjoyable tasting weed to share with friends. it goes well with playing in the park, going on a hike, or seeing outdoor music shows. A complimentary weed for summer, Brains Escape can also bring back that summer feeling during any season of the year.
IMHO-for those with severe pain: gather from a good, reliable coop and "limp" for the hills to smoke a bowl: alone. I thought that was why they call the last part "Escape" as if sharing it with other and partying with them is "escaping?" Nope-if you want to share, get some hash, a less expensive bud. Pack the bowl and pass the bong.
Don't use ANY form of "Brains" for sharing!!! On second thought: let them breathe second hand smoke and they can consider that a gift. And since I don't need people knowing my business and assuming I will get them fucked up for free: forget it!!!!!
I am sure that had I had a guy running the coop I was using, it would have been a much better bud: since the guy is good a photographing the marijuana of others' efforts for his site: then yeah: we'd still be doing busiess and since he can't weigh his bud: frequently-I did come out a gram or so ahead so
At least once in a while. Sigh, where ya buy-donate, sorry! The guy was an ass-and as far as I see it, this photo captured my sentiment very well:
JJ's assigned grade: A+++++
| Brains Escape [KC Brains] Indica Origins - Edelweiss x Brazil's Best x KC 606 Flowering - 63-77 days Harvest - End September |  |
Through the 1900s, Switzerland seemed to be on the verge of a progressive marijuana policy, indeed of becoming the next pot spot. KC Brains was among several growers who bred Swiss seeds in anticipation of a more liberal legal climate. Edelweiss is a distinctive Swiss strain that emerged in this period, based on a Swiss indica with a strong local reputation. Unfortunately, the Swiss government retreated from looser cannabis laws and began to crack down on pot culture, especially if it was "imported". Many growers who had tested Switzerland's evolving pot policies were charged as criminals or shown to the border.
KC Brains brought Edelweiss with him back to Holland, where he combined it with KC 606 and a Brazilian strain seasoned with sativa from South Ecuador.
The result is a fresh lemon weed whose buzz feels more "high" than "stoned". The Brains Escape pattern of growth is decidedly indica, delivering big plants with incredibly wide, dark, fat leaves. This strain's long growing season rewards outdoor growers who vegetate starter plants indoors or in a greenhouse, and then transplant outside to flower for 9-12 weeks before the frost starts.
This is an enjoyable tasting weed to share with friends. it goes well with playing in the park, going on a hike, or seeing outdoor music shows. A complimentary weed for summer, Brains Escape can also bring back that summer feeling during any season of the year.
IMHO-for those with severe pain: gather from a good, reliable coop and "limp" for the hills to smoke a bowl: alone. I thought that was why they call the last part "Escape" as if sharing it with other and partying with them is "escaping?" Nope-if you want to share, get some hash, a less expensive bud. Pack the bowl and pass the bong.
Don't use ANY form of "Brains" for sharing!!! On second thought: let them breathe second hand smoke and they can consider that a gift. And since I don't need people knowing my business and assuming I will get them fucked up for free: forget it!!!!!
I am sure that had I had a guy running the coop I was using, it would have been a much better bud: since the guy is good a photographing the marijuana of others' efforts for his site: then yeah: we'd still be doing busiess and since he can't weigh his bud: frequently-I did come out a gram or so ahead so
At least once in a while. Sigh, where ya buy-donate, sorry! The guy was an ass-and as far as I see it, this photo captured my sentiment very well:
 |
| real "Brains" from another more reputable Co-op. |
 |
| Cornholio's version-got a buzz but little else |
JJ's assigned grade: A+++++
Subscribe to:
Posts (Atom)